The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

If left untreated, Afib can lead to stroke, heart failure and premature cardiac death. But fortunately, Afib is treatable and, in some cases, preventable.

Articles were identified from EMBASE and MEDLINE using the medication name with the following search criteria: atrial fibrillation, clinical trials, pharmacoeconomic, humans, and English language.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary system that ...

drug interactions, and other factors will need to be considered on initiation of therapy, and future subgroup analyses may prove valuable for select patient populations. AF = atrial fibrillation ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...